Related Experiment Videos
[Myopathy and zidovudine]
O Mateo1, A Gato, P Ballesteros
1Servicio de Medicina Interna, Hospital Universitario de Getafe, Madrid.
Enfermedades Infecciosas Y Microbiologia Clinica
|October 1, 1992
Summary
This study investigated zidovudine-treated HIV patients, finding low rates of myopathy and creatine kinase elevation, likely due to lower drug doses. Clinical manifestations were minimal, suggesting zidovudine
Area of Science:
- Pharmacology
- Virology
- Neurology
Background:
- Zidovudine is an antiretroviral medication used in HIV treatment.
- Myopathy is a potential adverse effect of zidovudine therapy.
- Understanding the frequency of myopathy is crucial for patient management.
Purpose of the Study:
- To determine the incidence of myopathy in HIV patients receiving zidovudine.
- To analyze creatine kinase (CK) levels and clinical signs of muscle damage.
- To explore potential correlations between zidovudine dosage and myopathy.
Main Methods:
- Prospective study of 37 HIV-positive patients on zidovudine for over 180 days.
- Clinical history, physical examinations, and laboratory data (including CK levels) were collected.
- Patients were stratified by zidovudine dosage.
Main Results:
- Mean CK levels showed no statistically significant change from baseline (76.4 U/l to 83.3 U/l).
- 81% of patients experienced increased CK levels, with 8% showing clinically significant elevations.
- Only 5.4% of patients developed clinical myopathy symptoms.
Conclusions:
- The observed frequency of CK elevation and clinical myopathy was lower than reported in previous literature.
- Lower zidovudine doses may be associated with a reduced risk of myopathy.
- No significant association was found between myopathy and patient demographics (sex, age) or HIV risk factors.